Progenics (PGNX) volatility elevated into FDA approval of constipation treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Brean Capital Sees 'Significant Uptake' for Progenics' (PGNX) Oral Relistor
July 20, 2016 10:22 AM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and $14 price target on Progenics Pharmaceuticals (NASDAQ: PGNX) after the company and Valeant announced FDA approval of oral Relistor for the treatment of OIC in chronic non-cancer pain patients.
Aschoff commented, "Even with direct competitor Movantik on... More
Oral Relistor Approval the First of Many Progenics Pharmaceuticals (PGNX) Drivers - Needham & Company
July 20, 2016 9:16 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $11 price target on Progenics Pharmaceuticals (NASDAQ: PGNX) after the FDA approved oral Relistor. He called it the first of many upcoming drivers for the stock.
Messer commented, "PGNX shares are indicated up... More
Progenics Pharma (PGNX) Surges Over 20% as FDA Approval Oral RELISTOR
July 20, 2016 8:10 AM EDTProgenics Pharma (NASDAQ: PGNX) is ramping 21% in pre-open trade Wednesday after the company and Valeant Pharmaceuticals (NYSE: VRX) announced that the FDA has approved RELISTOR Tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic... More
BTIG Positive on Progenics Pharma (PGNX) Following FDA Approval of RELISTOR as OIC Treatment (VRX)
July 20, 2016 7:57 AM EDTBTIG affirms Progenics Pharmaceuticals (Nasdaq: PGNX) at Buy with a price target of $9 after Progenics and Valeant Pharma (NYSE: VRX)... More
